title: [Psoriasis induced by a TNF-alpha antagonist in a patient with ulcerative colitis].
abstract: Infliximab is an anti-TNF alpha and it has been used to treat ulcerative colitis refractory to other treatments since 2006, which is associated to quick induction and sustained remission of disease, as well as improvement of health related-quality of life. The most frequent adverse effects are formation of antibodies against anti-TNF alpha, acute allergic reactions, hypersensitivity reactions, lymphoproliferative diseases, susceptibility to infections, reactivation of latent extrapulmonary tuberculosis. We describe a case of psoriasis induced by anti-TNF, rarely described in literature. So we conducted a review on the mechanisms involved in this process, since this drug is also used in primary treatment of psoriasis.
authors: Universidade Federal da Paraiba, Brasil. roberta_ismael@hotmail.com
authors: Roberta Ismael Lacerda
authors: RI
authors: Machado
authors: Laís Medeiros
authors: LM
authors: Souto
authors: Eutilia Andrade Medeiros
authors: EA
authors: Freire
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab